Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.68 |
| ▸ | NPC1 | O15118 | 8/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.56 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.56 |
| ▸ | F12 | P00748 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8210918 | 0.83 | NPC1 (0.74) | RAB9ANPC1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL22720107 | 0.82 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL12121141 | 0.82 | NPC1 (0.68) | RAB9ANPC1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL787120 | 0.81 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2HPGDLMNA | |
| SCHEMBL28694288 | 0.81 | NPC1 (0.70) | RAB9ANPC1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL12121057 | 0.81 | NPC1 (0.70) | RAB9ANPC1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL22720141 | 0.81 | NPC1 (0.70) | RAB9ANPC1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL24405425 | 0.80 | NPC1 (0.69) | RAB9ANPC1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL22720180 | 0.79 | NPC1 (0.63) | RAB9ANPC1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL22720169 | 0.79 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748632-B2 | Positive allosteric modulators of group II mGluRs | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071503-A1 | POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS | GRM2, GRM1, GRIN2C | RAB9A 1823/4885NPC1 3399/4885SMN1; SMN2 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.